In Depth 21 Mar 2017
Rethinking Profits: Can a Socially Conscious Model work in Biotech?
As biopharma continues to weather a maelstrom of public scrutiny for its prices and profits, I asked executives about alternative models. Conventional wisdom in biotech is that the non-profit model can’t work in the industry: it takes a decade and billions in cash to develop a drug, with no guaranteed success. No investor would sink […]